Pacira Biosciences Inc Stock Price, News & Analysis

Pacira BioSciences, Inc. (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL at $35.6 million for February 2021, with average daily sales at 103% compared to last year. Despite ongoing COVID-19 challenges, the company observed strong demand for non-opioid pain management solutions, especially in outpatient settings. The impact of the pandemic continues to affect elective surgeries, but Pacira remains focused on leveraging EXPAREL and iovera° to enhance market presence. The company plans to report monthly sales data to provide transparency.

PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 2021 Barclays Global Healthcare Conference on March 9, 2021, at 10:55 AM ET. Interested parties can access the live audio from the company’s website's Events page, with a replay available for two weeks post-event. Pacira leads in non-opioid pain management solutions, notably with its long-acting local analgesic, EXPAREL®, launched in April 2012. The company aims to reduce opioid reliance, further emphasized by its acquisition of the iovera°® cryoanalgesia device in April 2019.

Pacira BioSciences (PCRX) reported record full-year 2020 revenue of $429.6 million, a 2% increase from 2019. The fourth quarter revenue reached $131.0 million, up 7% year-over-year. GAAP net income for the year was $145.5 million, or $3.41 per share. Despite challenges from the COVID-19 pandemic, EXPAREL sales drove strong growth, reaching $413.3 million. The European Commission approved EXPAREL for post-surgical pain, expanding market opportunities. Pacira remains committed to opioid alternatives amid the ongoing opioid crisis.

Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its fourth quarter and full year 2020 financial results on February 25, 2021, before U.S. market opening. A live conference call and webcast will follow at 8:30 a.m. ET, with participation accessible via a dedicated phone line and on their website. Pacira is committed to non-opioid pain management, focusing on its long-acting local analgesic, EXPAREL®, launched in 2012, and the iovera°® cryoanalgesia device acquired in 2019.

Pacira BioSciences reported preliminary unaudited net product sales of EXPAREL and iovera° totaling $34.9 million and $1.1 million, respectively, for January 2021. Average daily sales for EXPAREL reached 108% of the prior year, signaling ongoing growth despite COVID-19 challenges. The company emphasizes the successful adoption of EXPAREL in elective surgeries and its relevance in expedited recovery protocols. However, COVID-19 continues to negatively impact elective surgical schedules, affecting overall sales.

Pacira BioSciences (Nasdaq: PCRX) announced an equity investment in GeneQuine Biotherapeutics to support gene therapy development for osteoarthritis. The initial investment is €2 million, with an additional €4 million contingent on achieving specific milestones related to its lead product, GQ-303. Up to €2.5 million will be in convertible notes. This investment aligns with Pacira's mission to advance non-opioid pain management solutions. GeneQuine’s gene therapy vectors aim to enhance joint function and reduce pain and inflammation.

Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net revenue of $429.6 million for 2020, a 2.0% increase from 2019. The fourth-quarter net product sales for EXPAREL reached $125.3 million, up from $116.9 million in 2019. Daily sales of EXPAREL were at 109% of the previous year's average for Q4 and 111% for December. Despite COVID-19 disruptions, EXPAREL's growth in elective and non-elective procedures highlights its role in non-opioid pain management. The complete financial results will be reported in Q1 2021.

PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 7:30 AM ET. Investors can access the live audio via the company's website. A replay will be available for two weeks post-event. Pacira is a leader in non-opioid pain management and regenerative health solutions, known for its long-acting local analgesic, EXPAREL®. The company acquired the handheld cryoanalgesia device, iovera⁰, in April 2019 to further its mission of reducing opioid reliance.

Pacira BioSciences (Nasdaq: PCRX) announced preliminary net product sales of $38.1 million for EXPAREL and $0.8 million for iovera° in November 2020, marking a continuation of year-over-year growth despite COVID-19 challenges. The company is optimistic about EXPAREL's increasing adoption in outpatient settings and diverse surgical procedures. However, 2020 sales were affected by pandemic-related elective surgery postponements. The firm will provide ongoing updates on sales for greater transparency as market dynamics evolve post-pandemic.